The Inflation Reduction Act is set to transform how Medicare pays for prescription drugs, most notably by enabling Medicare to negotiate for the prices of certain high-cost medications. The pharmaceutical industry argues it will drastically reduce innovation, but a full analysis of its impacts on innovation requires considering not merely the number of new drugs produced but their clinical value. Several features of the negotiation process aim to minimize its impacts on innovation, particularly for drugs with high clinical value. The Biden Administration has also implemented several policies alongside the Inflation Reduction Act, such as the Advanced Research Projects Agency for Health and a National Biotechnology and Biomanufacturing Initiative, that are designed to reward and promote clinically valuable innovation. Taken together, these policies should go a long way toward mitigating any negative impacts on new drug development and may even better promote the development of higher-value drugs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985921 | PMC |
| http://dx.doi.org/10.1093/haschl/qxad004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Economic impact of reduced postoperative visits after inflatable penile prosthesis implantation.
J Comp Eff Res
January 2025
Boston Scientific Corporation; 100 Boston Scientific Way, Marlborough, MA, USA.
This study assessed the economic impact of reducing one postoperative visit following inflatable penile prosthesis (IPP) implantation. Scenario analyses were used to model the effects of eliminating one 30-min IPP postoperative visit from the expected 2.5 visits accounted for by the American Medical Association resource-based relative value scale data.
View Article and Find Full Text PDFComparing Otolaryngology Subspecialties' Changes in Medicare Reimbursement From 2013 to 2024.
Laryngoscope
January 2025
Department of Otolaryngology, Texas Tech University Health Sciences Center, Lubbock, Texas, U.S.A.
Objective: Identify differences in Medicare reimbursement changes for general otolaryngology, pediatric otolaryngology, head and neck oncology, laryngology, rhinology, otology, facial plastic and reconstructive surgery, and sleep surgery subspecialties from 2013 to 2024.
Methods: Subspecialty-based procedures' facility prices and relative value units (RVUs) were sourced from the Centers for Medicare & Medicaid Services' Physician Fee Schedule. Prices were adjusted for inflation, and the average percent change in facility price and RVUs for each subspecialty was calculated.
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation.
Expert Rev Pharmacoecon Outcomes Res
January 2025
IQVIA, Durham, NC.
Introduction: The 2022 Inflation Reduction Act (IRA) is expected to result in lower drug prices for Medicare beneficiaries in the United States (US). The Centers for Medicare & Medicaid Services (CMS) released the most recent draft guidance for the Medicare Drug Price Negotiation (DPN) program in May 2024.
Areas Covered: In August 2023, the list of 10 drugs selected for the DPN were published and the first round of negotiations are now complete.
Hospital Medicare Spending per Beneficiary: A Longitudinal Study.
J Healthc Manag
January 2025
Division of Health Care Delivery Research, Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Jacksonville, Florida.
Goal: While studies have examined quality and health outcomes related to the Centers for Medicare & Medicaid Services' (CMS's) Hospital Value-Based Purchasing (HVBP) Program, a significant gap exists in the literature regarding the relationship between pay-for-performance initiatives and hospital financial performance in the program's Efficiency and Cost Reduction domain. This study examined the association between hospitals' cost inefficiency and participation in the HVBP Program by estimating the probability and magnitude of improvement or achievement in the program's Efficiency and Cost Reduction domain.
Methods: The 2014-2019 Efficiency and Cost Reduction domain data were obtained from CMS and merged with the American Hospital Association's Annual Survey Database.
Detection of genetic variability in dairy cattle infectivity for bovine tuberculosis.
J Dairy Sci
January 2025
The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Midlothian EH25 9RG, United Kingdom. Electronic address:
This study investigated the genetics of bovine tuberculosis (bTB) infectivity in Holstein-Friesian dairy cows using British national data. The analyses included cows with recorded sires from herds affected by bTB outbreaks between 2000 and 2022. Animals were considered bTB-positive if they reacted positively to the skin test and/or had positive post-mortem findings.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!